Swiss - Delayed Quote CHF

BB Biotech AG (BIOEE.SW)

Compare
34.95
0.00
(0.00%)
As of December 20 at 3:27:15 PM GMT+1. Market Open.
Loading Chart for BIOEE.SW
DELL
  • Previous Close 34.95
  • Open 34.90
  • Bid --
  • Ask 35.85 x --
  • Day's Range 34.90 - 34.95
  • 52 Week Range 34.90 - 64.40
  • Volume 18,000
  • Avg. Volume 1,103
  • Market Cap (intraday) 2.114B
  • Beta (5Y Monthly) 0.83
  • PE Ratio (TTM) 15.26
  • EPS (TTM) 2.29
  • Earnings Date Feb 21, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

www.bbbiotech.ch/en/bb-biotech/

10

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIOEE.SW

View More

Performance Overview: BIOEE.SW

Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIOEE.SW
0.00%
MSCI WORLD
3.59%

1-Year Return

BIOEE.SW
45.73%
MSCI WORLD
19.02%

3-Year Return

BIOEE.SW
28.38%
MSCI WORLD
0.00%

5-Year Return

BIOEE.SW
28.38%
MSCI WORLD
62.41%

Compare To: BIOEE.SW

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOEE.SW

View More

Valuation Measures

Annual
As of 1/30/2025
  • Market Cap

    2.21B

  • Enterprise Value

    --

  • Trailing P/E

    15.26

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.51

  • Price/Book (mrq)

    0.86

  • Enterprise Value/Revenue

    18.78

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    281.64%

  • Return on Assets (ttm)

    0.31%

  • Return on Equity (ttm)

    5.64%

  • Revenue (ttm)

    44.51M

  • Net Income Avi to Common (ttm)

    125.36M

  • Diluted EPS (ttm)

    2.29

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.51B

  • Total Debt/Equity (mrq)

    12.31%

  • Levered Free Cash Flow (ttm)

    2.62M

Research Analysis: BIOEE.SW

View More

Company Insights: BIOEE.SW

Research Reports: BIOEE.SW

View More